How many stocks are there of Geneuro?
The current number of stocks of Geneuro is 24.84 M undefined.
Geneuro Stocks 2024
Geneuro Stocks
24.84 M
Ticker
GNRO.PA
ISIN
CH0308403085
WKN
A2AHDP
In 2024, Geneuro had 24.84 M outstanding stocks, a 0% change from the 24.84 M stocks in the previous year.
The Geneuro Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2025e | 24.84 |
| 2024e | 24.84 |
| 2023 | 24.84 |
| 2022 | 23.9 |
| 2021 | 21.28 |
| 2020 | 19.97 |
| 2019 | 14.56 |
| 2018 | 14.58 |
| 2017 | 14.59 |
| 2016 | 13.87 |
| 2015 | 12.12 |
| 2014 | 12.12 |
| 2013 | 12.12 |
Geneuro shares outstanding CH0308403085 · A2AHDP
The number of shares was Geneuro in 2023 — This indicates how many shares 24.843 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Geneuro earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Geneuro's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Geneuro’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Geneuro's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2013 | 12.12 M Aktien |
| 2014 | 12.12 M Aktien |
| 2015 | 12.12 M Aktien |
| 2016 | 13.87 M Aktien |
| 2017 | 14.59 M Aktien |
| 2018 | 14.58 M Aktien |
| 2019 | 14.56 M Aktien |
| 2020 | 19.97 M Aktien |
| 2021 | 21.28 M Aktien |
| 2022 | 23.9 M Aktien |
| 2023 | 24.84 M Aktien |
| 2024e | 24.84 M Aktien |
| 2025e | 24.84 M Aktien |
Geneuro Aktienanalyse
What does Geneuro do?
Geneuro SA is a biopharmaceutical company based in Plan-les-Ouates, Geneva, Switzerland. It was founded in 2007 and focuses on the development of innovative therapies for autoimmune diseases and other neurological disorders. Geneuro was founded based on research by Prof. Jean-Michel Goust, a renowned pain therapist and neuroimmunologist. In collaboration with distinguished scientists and experts in the field of neuroimmunology and neurovirology, he developed a new concept for combating autoimmune diseases of the nervous system, such as multiple sclerosis. Geneuro's business model is centered around developing novel therapeutics for chronic neurological disorders, particularly through immunomodulation. The drugs aim to help regulate the body's immune system to suppress inflammatory reactions in the brain, thereby preventing or at least reducing the adverse effects of autoimmune diseases. The company divides its activities into two main areas: research and development of novel therapeutics, and marketing of products. In the research and development field, Geneuro works closely with various partners such as universities, research institutes, and other companies. The aim is to translate the latest scientific knowledge in the fields of neuroimmunology and neurovirology into clinical practice in order to provide patients with better treatment options. Geneuro has focused on a specific class of drugs known as "anti-HERV," which stands for "human endogenous retroviruses." These retroviral particles make up approximately five percent of the human genome and are currently an active research area in neuroimmunology. Geneuro has developed a method to produce specific antibodies against these retroviruses and utilizes these antibodies as therapeutics in the fight against autoimmune diseases. The leading product of Geneuro in this area is GNbAC1, a novel monoclonal antibody preparation against the HERV virus, which was developed in collaboration with Merck Serono. GNbAC1 is currently in the clinical testing phase (Phase III) and has already shown promising results. It demonstrates significant efficacy in the treatment of multiple sclerosis and is also being tested for the treatment of other neuroimmunological diseases such as neuromyelitis optica and amyotrophic lateral sclerosis. In addition to GNbAC1, Geneuro has other products in the development phase. These include GNbAC2, a product specifically developed for the Japanese market in collaboration with Toyama Chemical Co., Ltd., and GNbAC-K9, a product for dogs designed to treat degenerative central nervous system disorders. Geneuro's second business area involves the marketing of its products. The company collaborates with both large pharmaceutical companies and smaller biotech companies worldwide to broaden the reach of their products. In recent years, Geneuro has established itself as a significant player in the field of neurological disorders. The company has developed promising therapies for autoimmune diseases that regulate the body's immune system in an innovative way. Geneuro's antibody preparations aim to target a specific class of proteins to contain inflammation in the brain and achieve broader efficacy in the treatment of neurological diseases such as MS. The company has set ambitious goals to improve its products and enhance its innovation capabilities, and will continue to drive significant developments in the future. Geneuro ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Geneuro's Shares Outstanding
Geneuro's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Geneuro’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Geneuro’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Geneuro’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Geneuro stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Geneuro are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Geneuro evolved in recent years?
The number of shares of Geneuro has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Geneuro as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Geneuro?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Geneuro pay?
Over the past 12 months, Geneuro paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geneuro is expected to pay a dividend of 0 EUR.
What is the dividend yield of Geneuro?
The current dividend yield of Geneuro is .
When does Geneuro pay dividends?
Geneuro pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Geneuro?
Geneuro paid dividends every year for the past 0 years.
What is the dividend of Geneuro?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Geneuro located?
Geneuro is assigned to the 'Health' sector.
Wann musste ich die Aktien von Geneuro kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Geneuro from 8/25/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 8/25/2024.
When did Geneuro pay the last dividend?
The last dividend was paid out on 8/25/2024.
What was the dividend of Geneuro in the year 2023?
In the year 2023, Geneuro distributed 0 EUR as dividends.
In which currency does Geneuro pay out the dividend?
The dividends of Geneuro are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Geneuro
Our stock analysis for Geneuro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geneuro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
